Acid-Base and Electrolyte Abnormalities Observed in Patients Receiving Cardiovascular Drugs

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 8, Issue 4, 2003, Pages 267-276

  Miltiadous, G ^a   Mikhailidis, D P ^b   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Acid base abnormalities; Cardiovascular drugs; Drug induced hyperkalemia; Electrolyte disorders; Hypokalemia; Hyponatremia; Metabolic alkalosis

Indexed keywords

ACETAZOLAMIDE; ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARDIOVASCULAR AGENT; CLONIDINE; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; HEPARIN; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; VASOPRESSIN;

CLINICAL PRACTICE; DISORDERS OF ACID BASE BALANCE; DRUG MECHANISM; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; METABOLIC ALKALOSIS; METABOLIC DISORDER; PHOSPHATURIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES;

EID: 0345824730     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840300800404     Document Type: Review

References (126)

1. Cannon PJ, Heinemann HO, Albert MS. "Contraction" alkalosis after diuresis of edematous patients with ethacrynic acid. Ann Intern Med 162:979-984, 1965
2. Garella S, Chang BS, Kahn SI. Dilution acidosis and contraction alkalosis: Review of a concept. Kidney Int 8:279-283, 1975
3. Hropot M, Fowler N, Karlmark B, et al. Tubular action of diuretics: Distal effects on electrolyte transport acidification. Kidney Int 28:477-489, 1985
4. Sabatini S, Kurtzman NA. The maintenance of metabolic alkalosis: Factors which decrease bicarbonate excretion. Kidney Int 25:357-361, 1984
5. Cohen JJ. Correction of metabolic alkalosis by the kidney after isometric expansion of extracellular fluid. J Clin Invest 47:1181-1192, 1968
6. Preisig PA, Toto RD, Alpern RJ. Carbonic anydrase inhibitors. Renal Physiol 10:136-159, 1987
7. Bear R, Goldstein M, Philipson M, et al. Effect of metabolic alkalosis on respiratory function in patients with obstructive lung disease. Can Med Assoc J 117:900-903, 1997
8. Miller PD, Berns AJ. Acute metabolic alkalosis perpetuating hypercapnia: A role for acetazolamide in chronic obstructive pulmonary disease. JAMA 238:2400-2401, 1977
9. Dorris R, Olivia JV, Rodman T. Dichlorphenamide, a potent carbonic anydrase inhibitor: Effect on alveoli-2 ventilations ventilation-perfusion relationship and diffusion in patients with chronic lung disease. Am J Med 36:79-84, 1964
10. Knutsen OH. New method for administration of hydrochloric acid in metabolic alkalosis. Lancet 1:953-956, 1985
11. Loon NR, Wilcox CS. Mild metabolic alkalosis impairs the natriuretic response to bumetadine in normal human subjects. Clin Sci 94:287-292, 1998
12. Duarte CG, Chomety F, Giebisch G. Effect of amiloride, ouabain, and furosemide on distal tubular function in the rat. Am J Physiol 221:632-639, 1971
13. Rose BD. Diuretics. Kidney Int 39:336-352, 1991
14. Morgan DB, Davidson C. Hypokalemia and diuretics: An analysis of publications. Br Med J 280:905-908, 1980
15. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and arrhythmias in hypertensive men. JAMA 267:1083-1089, 1992
16. Chapman MD, Hanrahan R, McEwen J, et al. Hyponatremia and hypokalemia due to indapamide. Med J Aust 6:219-221, 2002
17. Okusa MD, Velazquez H, Ellison DH, et al. Luminal calcium regulates potassium transport by the renal distal tubule. Am J Physiol 258:432-438, 1990
18. Kulley LH, Hulley SB, Cohen JD, et al. Unexpected effects of treating hypertension in men with electrocardiographic abnormalities: A critical analysis. Circulation 73:114-123, 1986
19. Cohen JD, Neaton JD, Prineas RJ, et al. Diuretics, serum potassium and ventricular arrhythmias in the Multiple Risk Factor Intervention Trial. Am J Cardiol 60:548-554, 1987
20. Tsuji H, Venditti FR Jr, Evans JC, et al. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 74:232-235, 1994
21. Wilcox CS. Metabolic and adverse effects of diuretics. Semin Nephrol 19:557-568, 1999
22. Multiple Risk Factor Intervention Trial Research Group. Baseline resting electrocardiographic abnormalities, anti-hypertensive treatment, and mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol 55:1-15, 1985
23. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 330:1852-1857, 1994
24. Carlsen JE, Kober L, Torp-Pedersen C, Johannsen P. Relation between dose of bedrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 300:975-978, 1990
25. Johnston GD, Wilson R, McDermott BJ, et al. Low-dose cyclopenthiazide in the treatement of hypertension: A one-year community-based study. Q J Med 78:135-143, 1991
26. Vardan S, Mehotra KG, Mookherjee S, et al. Efficacy and reduced metabolic side effects of a 15 mg chlorthalidone formulation in the treatment of mild hypertension. A multicenter study. JAMA 258:484-488, 1987
27. McVeigh G, Galloway DG, Johnston D. The case for low dose diuretics in hypertension: Comparison of low and conventional dose of cyclopenthiazide. Br Med J 297:95-98, 1988
28. France LV, Pahor M, Di Bari M, et al. Hypokalemia associated with diuretic use and cardiovascular events in the systolic hypertension in the elderly program. Hypertension 35:1025-1030, 2000
29. Schnaper HW, Freis ED, Friedman RG, et al. Potassium restoration in hypertensive patients made hypokalemic by hydrochlorothiazide. Arch Intern Med 149:2677-2681, 1989
30. Dyckner T, Wester P-O, Widman L. Amiloride prevents thiazide-induced intracellular potassium and magnesium losses. Acta Med Scand 224:25-30, 1988
31. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999
32. Griffing GT, Cole AG, Aurecchia SA, et al. Amiloride in primary hyperaldosteronism. Clin Pharmacol Ther 31:56-61, 1982
33. Ridgeway NA, Ginn DR, Alley K. Outpatient conversion of treatment to potassium-sparing diuretics. Am J Med 80:785-788, 1986
34. Kaplan NM, Carnegie A, Raskin P, et al. Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. N Engl J Med 312:746-749, 1985
35. Wuermser LA, Reilly C, Poindxter JR, et al. Potassium-magnesium citrate versus potassium chloride in thiazide-induced hypokalemia. Kidney Int 57:607-612, 2000
36. Fichman MP, Vorherr H, Kleeman CR, et al. Diuretic-induced hyponatremia. Ann Intern Med 75:853-863, 1971
37. Kamel KS, Bear RA. Treatment of hyponatremia: A quantitative analysis. Am J Kidney Dis 21:433-443, 1993
38. Friedman E, Shadel M, Halkin H, et al. Thiazide-induced hyponatremia: Reproducibility by single-dose challenge and an analysis of pathogenesis. Ann Intern Med 110:24-30, 1989
39. Ashraf N, Locksley R, Arrieff AI. Thiazide-induced hyponatremia associated with death or neurologic damage in outpatients. Am J Med 70:1163-1168, 1981
40. Ashouri OS. Severe-diuretic-induced hyponatremia in the elderly. Arch Intern Med 146:1355-1357, 1986
41. Sonnenblick M, Friedlander Y, Rosin AJ. Diuretic-induced severe hyponatremia: Review and analysis of 129 reported patients. Chest 103:601-606, 1993
42. Kennedy RM, Early L. Profound hyponatremia resulting from a thiazide-induced decrease in urinary diluting capacity in a patient with primarily polydipsia. N Engl J Med 282:1185-1186, 1970
43. Decaux G, Schlesser M, Coffernils M, et al. Uric acid, anion gap and urea concentration in the diagnostic approach to hyponatremia. Clin Nephrol 42:102-108, 1994
44. Szatalowicz VL, Miller PD, Lacher JW, et al. Comparative effects of diuretics on renal water excretion in hyponatremic oedematous disorders. Clin Sci 62:235-238, 1982
45. Maronde R, Milgrom M, Vlachakis ND, et al Response of thiazide-induced hypokalemia to amiloride. JAMA 249:237-241, 1983
46. Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: A systematic approach to laboratory diagnosis. CMAJ 166:1056-1062, 2002
47. Liamis G, Milionis H, Rizos E, et al. Mechanisms of hyponatremia in alcoholics. Alcohol Alcoholism 35:612-616, 2000
48. Du Bose TD Jr. Hyperkalemic metabolic acidosis: Pathophysiologic insights. Kidney Int 57:591-602, 1997
49. Siegel D, Hulley SB, Black DM, et al. Diuretics, serum and intracellular electrolyte levels, and ventricular arrhythmias in hypertensive men. JAMA 267(8):1083-1089, 1992
50. Ryan MP. Diuretics and potassium/magnesium depletion. Directions for treatment. Am J Med 82:38-47, 1987
51. Milionis HJ, Alexandrides GE, Liberopoulos EN, et al. Hypomagnesemia and concurrent acid-base and electrolyte abnormalities in patients with congestive heart failure. Eur J Heart Fail 4:167-173, 2002
52. Quamme GA. Renal magnesium handling: New insights in understanding old problems. Kidney Int 52:1180-1195, 1997
53. Ellison DH. Diuretic drugs and the treatment of edema: From clinic to bench and back again. Am J Kidney Dis 23:623-643, 1994
54. Quamme GA. Effect of furosemide on calcium and magnesium transport in the rat nephron. Am J Physiol 241:F340-347, 1981
55. Shimizu T, Nakamura M. Ouabain-induced cell swelling in rabbit connecting tubule: Evidence for thiazide-sensitive Na(+)-Cl-cotransport. Pflugers Arch 421:314-321, 1992
56. Dai LJ, Friedman PA, Quamme GA. Cellular mechanisms of chlorothiazide and cellular potassium depletion on Mg2+ uptake in mouse distal convoluted tubule cells. Kidney Int 51:1008-1017, 1997
57. Frindt G, Sackin H, Palmer LG. Whole-cell currents in rat cortical collecting tubule: Low-Na diet increases amiloride-sensitive conductance. Am J Physiol 258:F562-F567, 1990
58. Dai LJ, Raymond L, Friedman PA, et al. Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells. Am J Physiol 272:F249-256, 1997
59. Dai LJ, Quamme GA. Intracellular Mg2+ and magnesium depletion in isolated renal thick ascending limb cells. J Clin Invest 88:1255-1264, 1991
60. Ralston MA, Murnane MR, Unverferth DV, et al. Serum and tissue magnesium concentrations in patients with heart failure and serious ventricular arrhythmias. Ann Intem Med 113:841-846, 1990
61. Friedman PA, Gesek FA. Calcium transport in renal epithelial cells. Am J Physiol 264:181-198, 1993
62. Gesek FA, Friedman PA. On the mechanism of parathyroid hormone stimulation of calcium uptake by mouse distal convoluted cells. J Clin Invest 90:749-758, 1992
63. Friedman PA, Gesek FA. Vitamin D3 accelerates PTH-dependent calcium transport in distal convoluted tubule cells. Am J Physiol 265:F300-F308, 1993
64. Friedman PA. Basal and hormone-activated calcium absorption in mouse renal thick ascending limbs. Am J Physiol 254:F62-70, 1988
65. Lemann J Jr, Gray RW, Maierhofer WJ, et al. Hydrochlorothiazide inhibits bone resorption in men despite experimentally elevated serum 1,25-dihydroxyvitamin D concentrations. Kidney Int 28:951-958, 1985
66. Costanzo LS. Localization of diuretic action in microperfused rat distal tubules: Ca and Na transport. Am J Physiol 248:F527-535, 1985
67. Gesek FA, Friedman PA. Mechanism of calcium transport stimulated by chlorothiazide in mouse distal convoluted tubule cells. J Clin Invest 90:429-438, 1992
68. Lajeunesse D, Bouhtiauy I, Brunette MG. Parathyroid hormone and hydrochlorothiazide increase calcium transport by the luminal membrane of rabbit distal nephron segments through different pathways. Endocrinology 134:35-41, 1994
69. Shimizu T, Nakamura M, Yoshitomi K, et al. Interaction of trichlormethiazide or amiloride with PTH in stimulating Ca2+ absorption in rabbit CNT. Am J Physiol 261:F36-F43, 1991
70. Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 118:666-673, 1993
71. Jones G, Nguyen T, Sambrook PN, et al. Thiazide diuretics and fractures: Can meta-analysis help? J Bone Miner Res 10:106-111, 1995
72. Christensson T, Hellstrom K, Wengle B. Hypercalcemia and primary hyperparathyroidism: Prevalence in patients receiving thiazides as detected in a health screen. Arch Intern Med 137:1138-1142, 1977
73. Koppel MH, Massry SG, Shinaberger JH, et al. Thiazide-induced rise in serum calcium and magnesium in patients on maintenance hemodialysis. Ann Intern Med 72(6):895-901, 1970
74. Dimeglio LA, White KE, Econs MJ. Disorders of phosphate metabolism. Endocrinol Metab Clin North Am 29:591-609, 2000
75. DuBose TD Jr, Good DW. Effect of diuretics on renal acid-base transport. Semin Nephrol 8:282-294, 1988
76. Greenblatt DJ, Koch-Weser J. Adverse reaction to spironolactone. JAMA 225:40-43, 1973
77. Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intem Med 90:338-340, 1979
78. Szylman P, Better OS, Chaimowitz C, et al. Role of hyperkalemia in the metabolic acidosis of isolated hypoaldosteronism. N Engl J Med 294:361-365, 1976
79. Sebastian A, Schambelan M. Amelioration of type 4 renal tubular acidosis in chronic renal failure with furosemide. Kidney Int 12:534-538, 1977
80. Perazella MA. Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med 109:307-314, 2000
81. Siamopoulos KC, Elisaf M, Katopodis K. Iatrogenic hyperkalaemia points to consider in diagnosis and management. Nephrol Dial Transplant 13:2402-2406, 1998
82. Ponce SP, Jennings AE, Madias NE, et al. Drug-induced hyperkalemia. Medicine 64:357-370, 1985
83. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med 147:867-869, 1987
84. Chiu TF, Bullard MJ, Chen JC, et al. Rapid life threatening hyperkalemia after addition of amiloride HCl/hydrochlorothiazide to angiotensin-converting enzyme inhibitor therapy. Ann Emerg Med 30:612-615, 1997
85. Papadimitriou M, Vyzantiadis A, Milionis A, et al. The effect of spironolactone in hypertensive patients on regular haemodialysis and after renal allotransplantation. Life Support Systems 1:197-206, 1983
86. DeFronzo RA. Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 17:118-134, 1980
87. Gupta P, Franco-Saenz R, Mulrow PJ. Locally generated angiotensin II in the adrenal gland regulates basal, corticotropin-, and potassium-stimulated aldosterone secretion. Hypertension 25:443-448, 1995
88. Pratt JH. Role of angiotensin II in potassium-mediated stimulation of aldosterone secretion in the dog. J Clin Invest 70:667-672, 1982
89. Textor SC, Bravo EL, Fouad FM, et al. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with captopril. Am J Med 73:719-725, 1982
90. Grossman A, Eckland D, Price P, et al. Captopril: Reversible renal failure with severe hyperkalaemia. Lancet 1:712, 1980
91. Packer M, Lee WH. Provocation of hyper-and hypokalemic sudden death during treatment with and withdrawal of converting-enzyme inhibition in severe chronic congestive heart failure. Am J Cardiol 57:347-348, 1986
92. Burnakis TG, Mioduch HJ. Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia. Arch Intern Med 144:2371-2372, 1984
93. Ahuja TS, Freeman D Jr, Mahnken JD, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 20:268-272, 2000
94. Knoll GA, Sahgal A, Nair RC, et al. Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112:110-114, 2002
95. Keilani T, Danesh FR, Schlueter WA, et al. A subpressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 33:450-457, 1999
96. Oster JR, Preston RA, Materson BJ. Fluid and electrolyte disorders in congestive heart failure. Semin Nephrol 14:485-505, 1994
97. Hussain Z, Shaikh A, Taylor HC, et al. Syndrome of inappropriate antidiuretic hormone secretion associated with lisinopril. Ann Pharmacother 34:176-179, 2000
98. Elisaf M, Theodorou J, Pappas C, et al. Successful treatment of hyponatremia with angiotensin converting enzyme inhibitors in patients with congestive heart failure. Cardiology 86:477-480, 1995
99. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotesnin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 75:793-795, 1995
100. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 25:37-46, 1995
101. Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. VAL-K Study Group. Kidney Int 58:2084-2092, 2000
102. Bauer JH. Effects of propranolol therapy on renal function and body fluid composition. Arch Intern Med 143:927-931, 1983
103. Sterns RH, Spital A. Disorders of internal potassium balance. Semin Nephrol 7:399-415, 1987
104. Lim M, Linton RA, Wolff CB, et al. Propranolol, exercise, and arterial plasma potassium. Lancet 2:591, 1981
105. Bethune DW, McKay R. Paradoxical changes in serum-potassium during cardiopulmonary bypass in association with non-cardioselective beta blockade. Lancet 2:380-381, 1978
106. Lowenthal DT, Affrime MB, Rosenthal L, et al. Dynamic and biochemical responses to single and repeated doses of clonidine during dynamic physical activity. Clin Pharmacol Ther 32:18-24, 1982
107. Castellino P, Bia MJ, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int 37:793-798, 1990
108. Phelps KR, Oh MS, Carroll HJ. Heparin-induced hyperkalemia: Report of a case. Nephron 25:254-258, 1980
109. Sherman RA, Ruddy MC. Suppression of aldosterone production by low-dose heparin. Am J Nephrol 6:165-168, 1986
110. O'Kelly R, Magee F, McKenna TJ. Routine heparin therapy inhibits adrenal aldosterone production. J Clin Endocrinol Metab 56:108-112, 1983
111. Edes TE, Sunderrajan EV. Heparin-induced hyperkalemia. Arch Intem Med 145:1070-1072, 1985
112. Oster JR, Singer I, Fishman LM. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 98:575-586, 1995
113. Gonzalez-Martin G, Diaz-Molinas MS, Martinez AM, et al. Heparin-induced hyperkalemia: A prospective study. Int J Clin Pharmacol Ther Toxicol 29:446-450, 1991
114. Durand D, Ader JL, Rey JP, et al. Inducing hyperkalemia by converting enzyme inhibitors and heparin. Kidney Int Suppl 25:S 196-S 197, 1988
115. Antonipillai I, Wang Y, Horton R. Tumor necrosis factor and interleukin-1 may regulate renin secretion. Endocrinology 126(1):273-278, 1990
116. Canova CR, Fischler MP, Reinhart WH. Effect of low-molecular-weight heparin on serum potassium. Lancet 349:1447-1448, 1997
117. Wiggam MI, Beringer TR. Effect of low-molecular-weight heparin on serum concentrations of potassium. Lancet 350:292-293, 1997
118. Sherman DS, Kass CL, Fish DN. Fludrocortisone for the treatment of heparin-induced hyperkalemia. Ann Pharmacother 34:606-610, 2000
119. Smith TW. Digitalis. Mechanisms of action and clinical use. N Engl J Med 318:358-365, 1988
120. Asplund J, Edhag O, Mogensen L, et al. Four cases of massive digitalis poisoning. Acta Med Scand 189:293-297, 1971
121. Reza MJ, Kovick RB, Shine KI, et al. Massive intravenous digoxin overdosage. N Engl J Med 291:777-778, 1974
122. Lown B, Black A, Moore FD. Digitalis, electrolytes and the surgical patient. Am J Cardiol 6:309-311, 1960
123. Shannon M, Lovejoy FH Jr. Hypokalemia after theophylline intoxication: The effects of acute versus chronic poisoning. Arch Intern Med 149:2725-2729, 1989
124. Liberopoulos EN, Alexandridis GH, Christidis DS, et al. SIADH and hyponatremia with theophylline. Ann Pharmacother 36:1180-1182, 2002
125. Odeh M, Schiff E, Oliven A. Hyponatreamia during therapy with amiodarone. Arch Intern Med 159:2599-2600, 1999
126. Goldenberg IF, Olivari MT, Levine TB, et al. Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy. Am J Cardiol 63:843, 1989